Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs US Bancorp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.04 (market cap $29.60B), while US Bancorp trades at $64.75 (market cap $100.17B). The key difference: US Bancorp is far larger — about 3.4× Alnylam Pharmaceuticals, Inc.'s market cap, and US Bancorp pays a 3.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | USB | |
|---|---|---|
Market Cap | $29.60B | $100.17B |
Sector | Health | Financials |
52-Week High | $491.22 | $64.47 |
52-Week Low | $205.48 | $45.28 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
U.S. Bancorp (USB) trades at $64.80, up 0.95% today, with a bullish technical trend and strong support at $64. The company reported Q2 2026 EPS of $1.35, beating estimates, and maintains a net income margin of 27.61%. Recent news highlights institutional buying and upbeat Q2 results, reinforcing positive sentiment.
The outlook is positive with a consensus price target of $70.27, indicating potential upside. Risks include rising interest rate sensitivity and competitive pressures. Earnings growth and dividend stability support a favorable investment case, though macroeconomic factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
